King's Research Portal

Document Version
Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):
Kolarik, M., Indra, R., Adam, V., Heger, Z., Kopeckova, K., Arlt, V. M., & Stiborova, M. (2019). Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro. *Neuroendocrinology Letters*, *39*(7), 515-524. http://www.nel.edu/userfiles/articlesnew/1554982348_39_7_kolarik_515_-pdf.pdf

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 04. Oct. 2023

Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 *in vitro*

Matus Kolarik[1], Radek Indra PhD[1], Prof Vojtech Adam[2], Zbynek Heger PhD[2], Katerina Kopeckova MD[3], Volker M. Arlt PhD[4,5], Prof Marie Stiborova[1]

[1] Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic

[2] Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, 61300 Brno, Czech Republic

[3] Department of Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 150 06 Prague 5, Czech Republic

[4] Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom

[5] NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England and Imperial College London, 150 Stamford Street, London SE1 9NH, United Kingdom

Corresponding author: Prof. RNDr. Marie Stiborova, DrSc, Department of Biochemistry, Faculty of Science, Charles University, Prague, Albertov 2030, 128 40 Prague 2, Czech Republic; Tel.: +420 22195121285; fax: +420 221951283; E-MAIL: stiborov@natur.cuni.cz

Running headline: Tyrosine kinase inhibitors influence the cytochrome P450-mediated metabolism of ellipticine

KEYWORDS

Tyrosine kinase inhibitors; Ellipticine; Cytochromes P450; Peroxidases; Ellipticine oxidation.

OBJECTIVES: Vandetanib¸ lenvatinib, and cabozantinib are tyrosine kinase inhibitors (TKIs) targeting VEGFR subtypes 1 and 2, EGFR and the RET-tyrosine kinase, thus considered as multiple TKIs. These TKIs have already been approved for treating patients suffering from thyroid cancer and renal cell carcinoma. Ellipticine, a DNA-damaging drug, is another anticancer agent that is effective against certain tumors of the thyroid gland, ovarian carcinoma, breast cancer and osteolytic breast cancer metastasis. Its anticancer efficiency is dictated by its oxidation with cytochrome P450 (CYP) and peroxidase enzymes. A number of studies testing the effectiveness of individual anticancer drugs, the pharmacological efficiencies of which are affected by their metabolism, alone or in a combination with other cytostatics demonstrated that such combination can have both positive and negative effects on treatment regimen. The aim of this study was to study the effect of vandetanib, lenvatinib and cabozantinib on oxidation of ellipticine which dictates its pharmacological efficiency.

METHODS: Ellipticine oxidation catalyzed by hepatic microsomes, recombinant CYP enzymes and peroxidases (horseradish peroxidase, lactoperoxidase and myeloperoxidase) and the effect of TKIs (vandetanib, lenvatinib and cabozantinib) on this oxidation were analyzed by HPLC used for separation of ellipticine metabolites and quantification of their amounts formed during oxidation.

RESULTS: The CYP enzymatic system oxidizes ellipticine up to five metabolites (9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N^2- oxide), while peroxidases form predominantly ellipticine dimer. Ellipticine oxidation catalyzed by rat and human hepatic microsomes was inhibited by vandetanib and cabozantinib, but essentially no inhibition was caused by lenvatinib. Of individual CYP enzymes catalyzing oxidation of ellipticine, TKIs inhibited oxidation of ellipticine catalyzed by CYP2D6 > 2D1 > 2C9 > 3A1 > 3A4, the CYP enzymes participating in ellipticine oxidation to metabolites increasing the ellipticine anticancer efficiency. On the contrary, they have essentially no inhibition effect on ellipticine oxidation catalyzed by CYP1A1 and 1A2, which are the enzymes that predominantly detoxify this drug. All tested TKIs had essentially no effect on oxidation of ellipticine by used peroxidases.

CONCLUSION: The results found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib cause a decrease in oxidative activation of DNA-damaging drug ellipticine by several CYP enzymes *in vitro* which might lead to a decrease in its pharmacological efficiency. In contrast, they practically do not influence its detoxification catalyzed by CYP1A1, 1A2 and peroxidases. The present study indicates that tested TKIs seem not to have a potency to increase ellipticine anticancer efficiency.

Abbreviations

CYP - cytochrome P450

DMSO – dimethyl sulfoxide

HRP - horseradish peroxidase

EGFR - epidermal growth factor receptor

LPO - lactoperoxidase

74 MPO - myeloperoxidase

75 NADPH:CYP oxidoreductase - POR

76 ND – not determined

77 NQ – not quantified

78 RET – rearranged during transfection protooncogene

79 r.t. – retention time

80 TK – tyrosine kinase

81 TKI – tyrosine kinase inhibitor

82 VEGFR - vascular endothelial growth factor receptor

83

84 **INTRODUCTION**

85 Cancer treatment is one of the most difficult problems in clinic practice. The drugs
86 utilized for cancer chemotherapy have usually a narrow therapeutic index, and often
87 the produced responses are only palliative as well as unpredictable. Namely,
88 although the drugs are directed toward certain biomacromolecules, they do not
89 discriminate between rapidly dividing tumor *vs.* non-malignant cells [Heger et al.,
90 2013]. In contrast, targeted therapy that has been introduced in recent years is
91 directed against cancer-specific targets and signaling pathways, and thus provides
92 more limited nonspecific mechanisms [Arora and Scholar, 2005]. One of the most
93 promising targets are receptor tyrosine kinases (TKs), the enzymes that selectively
94 phosphorylate the hydroxyl moieties of tyrosine residues on signal transduction
95 molecules with a phosphate moiety from adenosine triphosphate [Reibenwein and
96 Krainer, 2008; Hartmann et al., 2009]. Vandetanib, lenvatinib and cabozantinib are
97 tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor
98 (VEGFR) subtypes 1 and 2, epidermal growth factor receptor (EGFR) and the RET

99 (rearranged during transfection)-tyrosine kinase, thus considered as multiple TKIs.
100 These TKIs have already been approved for treating patients suffering from thyroid
101 cancer and renal cell carcinoma, and further clinical trials are ongoing for prostate
102 cancer and glioblastoma multiforme [Greenhill, 2017; Roviello et al., 2018; Abdelaziz
103 and Vaishampayan, 2017].

104 Ellipticine (Fig. 1) and its derivatives are other anticancer agents that are
105 effective against certain tumors of the thyroid gland (anaplastic thyroid carcinoma,
106 medullary thyroid carcinoma), ovarian carcinoma, breast cancer and osteolytic breast
107 cancer metastasis [Stiborova et al., 2001; 2011; Kumarasamy and Sun, 2017]. The
108 predominant mechanisms of ellipticine's biological effects were suggested to be (i)
109 intercalation into DNA [Garbett and Graves, 2004; Tmejova et al., 2014] and (ii)
110 inhibition of topoisomerase II [Garbett and Graves, 2004; Stiborova et al., 2011;
111 Kizek et al., 2012; Stiborova and Frei, 2014]. Further, ellipticine anticancer
112 efficiencies are dependent on its metabolism leading both to the activation
113 metabolites causing DNA damage (covalent DNA adducts) and their detoxification to
114 products that are excreted. Ellipticine is oxidized by microsomal cytochrome P450
115 (CYP) enzymes and peroxidases. Its oxidative activation by CYP3A, 2C and 2D
116 leads to formation of 12-hydroxy- and 13-hydroxyellipticine, reactive metabolites that
117 are converted to ellipticine-12-ylium and ellipticine-13-ylium, binding to DNA, while
118 formation 9-hydroxyellipticine and the ellipticine dimer catalyzed by CYP1A1/2 and
119 peroxidases, respectively, are considered to be detoxification pathway of its
120 metabolism (Fig. 1) [Stiborova et al., 2004; 2011; Stiborova and Frei, 2014].

121 Overall, in cancer chemotherapy, serious clinical consequences may occur
122 from small alterations in drug metabolism affecting drug pharmacokinetics. Such
123 alterations might be caused by several reasons, of them the drug-drug interactions

124 influencing their metabolism might be one of most important. A number of studies
125 testing the effectiveness of individual anticancer drugs alone or in a combination with
126 other cytostatics demonstrated that such combination can have additive and/or
127 contradictory effects on treatment regimen [for a review, see Stiborova et al., 2012a].
128 In this context, ellipticine anticancer effects have been found to be increased by
129 another drug, an histone deacetylase inhibitor valproic acid (VPA), which is mediated
130 by its influence on ellipticine metabolism [Poljakova et al., 2011; Cerna et al., 2018].
131 The aim of this study was to investigate the effect of additional anticancer drugs, TKIs
132 vandetanib, lenvatinib and cabozantinib, namely, their effects on oxidative
133 metabolism of ellipticine dictating its pharmacological efficiency.
134

135 MATERIALS AND METHODS

136 *Chemicals and material*

137 Vandetanib, lenvatinib and cabozantinib were from LC Laboratories
138 (Woburn, MA, USA), ellipticine, NADPH, horseradish peroxidase (HRP) type VI,
139 bovine lactoperoxidase (LPO), human myeloperoxidase (MPO) and other chemicals
140 were purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity (purity meets
141 the standards of American Chemical Society), unless noted otherwise. Rat
142 microsomes were isolated from liver of male rats (Wistar) as described previously
143 [Stiborova et al., 2001]. Male human hepatic microsomes (pooled sample) (sample
144 LOT: 3043885), were from Gentest Corp. (Woburn, MA, USA). Human and rat
145 recombinant enzymes were used in the forms of Supersomes™ that are microsomes
146 isolated from insect cells transfected with a baculovirus construct containing cDNA of
147 human and rat CYP enzymes (CYP1A1, 1A2, 2C9, 2D1/6, 3A1/4), and which also

148 express NADPH:CYP oxidoreductase (POR) and/or cytochrome b_5. They were
149 purchased from Gentest Corp. (Woburn, MA, USA).

150 *Oxidation of ellipticine by hepatic microsomes and CYP enzymes and the effect of*
151 *TKIs on this oxidation*

152 Unless stated otherwise, incubation mixtures used to study ellipticine metabolism
153 contained the following in a final volume of 500 µl: 100 mM potassium phosphate
154 buffer (pH 7.4), 1 mM NADPH, rat or human hepatic microsomes (0.25 mg protein),
155 or rat or human recombinant CYPs in Supersomes^{TM} (50 pmol) and 50 µM ellipticine
156 dissolved in 5 µl dimethyl sulfoxide (DMSO). When the effect of TKIs vandetanib,
157 lenvatinib and cabozantinib was investigated, the incubation mixtures also contained
158 50 µM TKIs dissolved in 5 µl DMSO. The reaction was initiated by adding ellipticine.
159 In the control incubations, either microsomes or CYP or NADPH or TKIs or ellipticine
160 were omitted. After incubation at 37°C for 20 min in open plastic Eppendorf tubes
161 (ellipticine oxidation was linear up to 30 min of incubation [Kotrbova et al., 2006;
162 Stiborova et al., 2006]) and 5 µl of 1 mM phenacetine in methanol was added as an
163 internal standard, the reaction was stopped by extraction with ethyl acetate (twice
164 with ethyl acetate, 2 x 1 ml). The extracts were evaporated, dissolved in 50 µl of
165 methanol and ellipticine and its metabolites were separated by HPLC (5 mm
166 Ultrasphere ODS Beckman, 4.6 x 250 mm preceded by a C-18 guard column); the
167 eluent was 64% methanol plus 36% of 5 mM heptane sulfonic acid in 32 mM acetic
168 acid in water with a flow rate of 0.7 ml/min, detection was at 296 nm. Ellipticine
169 metabolites eluted by HPLC were characterized by mass spectroscopy and/or NMR
170 as described [Stiborova et al., 2004; 2006]. Up to five ellipticine metabolites with the
171 retention times of 5.8, 6.0, 6.8, 7.0 and 9.9 min, corresponding to 9-hydroxy-, 12-
172 hydroxy-, 13-hydroxy-, 7-hydroxyellipticine and ellipticine N^2- oxide, were separated

173 [Stiborova et al., 2004; 2006]. Recoveries of ellipticine metabolites were
174 approximately 95%. In the incubation mixture containing lenvatinib, one broad peak
175 of this TKI eluting with a retention time (r.t.) of 5.8 min overlapped the peaks of 9-
176 hydroxy- and/or 12-hydroxyellipticine. Therefore, their amounts could not been
177 evaluated (determined).

178 *Oxidation of ellipticine by peroxidases and the effect of TKIs on this oxidation*

179 Incubation mixtures used to evaluate the oxidation of ellipticine by the studied
180 peroxidases (HRP, LPO and MPO), in a final volume of 500 µl, consisted of 100 mM
181 potassium phosphate buffer (pH 7.4), 10 µM ellipticine (dissolved in 1 µl DMSO), 1, 2
182 or 2 µg of HRP, LPO or MPO, respectively, and 50 µM hydrogen peroxide. When the
183 effect of TKIs vandetanib, lenvatinib and cabozantinib was investigated, the
184 incubation mixtures also contained 10 µM TKIs dissolved in 1µl DMSO. All reactions
185 were initiated by adding ellipticine dissolved in DMSO. Control incubations were
186 either without peroxidases, or without hydrogen peroxide, or without TKIs, or without
187 ellipticine. Incubations were carried out at 37°C for 15 min. After incubations, 5 µl of 1
188 mM of phenacetine in methanol was added as an internal standard, and the ellipticine
189 metabolites were extracted twice with ethyl acetate (2 × 1 ml) as described [Stiborova
190 et al., 2007]. The extracts were evaporated and dissolved in 50 µl of methanol.
191 Ellipticine and its metabolites were separated by HPLC. The column used was a 5
192 µm Ultrasphere ODS (Beckman, 4.6 × 250 mm) preceded by a C-18 guard column.
193 The eluents were 45-90% methanol in 10 mM ammonium acetate (pH 2.8), with flow
194 rate of 0.8 ml/min, detection was at 296 nm [Stiborova et al., 2004; 2007; Poljakova
195 et al., 2005]. Recoveries of ellipticine metabolites were around 95% in the presence
196 of enzymes without hydrogen peroxide. One product peak with r.t. of 16.0 min and
197 unconverted ellipticine with r.t. of 11.8 min were separated by HPLC. The ellipticine

198 metabolite was identified by mass spectroscopy, NMR and/or cochromatography on
199 HPLC to be ellipticine dimer as described previously [Stiborova et al., 2007].
200 *Statistical analyses*
201 For statistical data analysis we used Student's *t*-test. All *P*-values are two-tailed and
202 considered significant at the 0.05 level.
203

204 **RESULTS AND DISCUSSION**

205 *The effect of vandetanib, lenvatinib and cabozantinib on ellipticine oxidation*
206 *catalyzed by rat and human hepatic microsomes*

207 In the study, liver microsomes of rats and humans were used as model *in vitro*
208 systems, because rats have been shown to mimic the metabolism of ellipticine in
209 humans, and the liver rich in enzymes biotransforming xenobiotics including drugs is
210 the major organ responsible for metabolism of these chemicals [Stiborova et al.,
211 2006; Stiborova and Frei, 2014]. Ellipticine was oxidized by rat and human hepatic
212 microsomes up to three metabolites (9-hydroxy-, 12-hydroxy- and 13-
213 hydroxyellipticine) (Fig. 2) that were separated by HPLC (see insert in Fig. 2A). Other
214 two metabolites (7-hydroxyellipticine and ellipticine N^2-oxide) (Stiborova et al., 2004;
215 2006) were formed at very low amounts (if any) and, therefore, they were not
216 quantified (NQ) (Fig. 2).

217 Of ellipticine reaction products formed in the systems, 9-hydroxyellipticine is
218 considered as a detoxification metabolic product, whereas 12-hydroxy- and 13-
219 hydroxyellipticine are the activation metabolites participating in an increase in
220 ellipticine anticancer efficiency due to the formation of covalent DNA adducts
221 [Stiborova et al., 2011; Stiborova and Frei, 2014]. The same HPLC method utilized
222 for separation of ellipticine metabolites was also used to examine the effect of TKIs

223 on ellipticine oxidation. Vandetanib and cabozantinib were eluted from the HPLC
224 column at retention times different from those of ellipticine and its metabolites (data
225 not shown). However, lenvatinib was eluted as a broad peak at retention time of 5.8
226 min, frequently overlapping the peaks of 9-hydroxy- and/or 12-hydroxyellipticine (see
227 insert in Fig. 2B). Therefore, formation of these metabolites could not been
228 determined (ND). Formation of several ellipticine metabolites in these microsomal
229 systems was inhibited by the tested TKIs. Oxidation of ellipticine to its metabolites (9-
230 hydroxy-, 12-hydroxy- and 13-hydroxyellipticine) by rat hepatic microsomes was
231 inhibited by vandetanib and cabozantinib, while lenvatinib had no effect on ellipticine
232 oxidation to 13-hydroxyellipticine catalyzed by this rat enzymatic system (Fig. 2A). In
233 the case of human hepatic microsomes, tested TKIs did not inhibit the formation of an
234 ellipticine detoxification product 9-hydroxyellipticine, while except of lenvatinib, they
235 inhibited formation of the activation metabolites 12-hydroxy- and 13-
236 hydroxyellipticine. In contrast, a slight, but non-significant (P = 0.1) increase in
237 ellipticine oxidation to 13-hydroxyellipticine was produced by lenvatinib in human
238 microsomes (Fig. 2B).

239 *The effect of vandetanib, lenvatinib and cabozantinib on ellipticine oxidation*
240 *catalyzed by rat and human recombinant CYPs*

241 In order to evaluate the impact of TKIs on inhibition of ellipticine oxidation
242 catalyzed by individual microsomal CYP enzymes, we investigated their effects on
243 ellipticine oxidation by several CYP enzymes, especially those, which are known to
244 be essential for its oxidation. Namely, again the CYPs important both for its oxidative
245 detoxification to metabolites that are excreted from the body and for its activation to
246 reactive metabolites responsible for formation of covalent DNA adducts leading to
247 higher ellipticine anticancer efficiencies [for a review, see Stiborova et al., 2011;

248 Stiborova and Frei, 2014]. For such a study, rat and human recombinant CYPs were
249 utilized. Of the CYP enzymes predominantly oxidizing ellipticine, rat and human
250 CYP1A1/2 which mainly detoxify ellipticine, and human CYP2C9, rat CYP2D1 and its
251 human orthologue CYP2D6, and rat CYP3A1 and its human orthologue CYP3A4, the
252 enzymes which activate ellipticine to more reactive metabolites, were employed.
253 Depending on individual CYPs, they oxidized ellipticine up to five metabolites, 9-
254 hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellipticine N^2- oxide
255 (Figs. 3 and 4).

256 Of the used CYPs, TKIs had essentially no inhibitory effect on ellipticine
257 oxidation catalyzed by CYP1A1 and 1A2. These CYPs oxidized ellipticine up to four
258 metabolites, 9-hydroxy-, 12-hydroxy-, 13-hydroxy- and 7-hydroxyellipticine, while no
259 ellipticine N^2-oxide was detectable (Fig. 3). In contrast to no inhibition of ellipticine
260 oxidation mediated by CYP1A1 and 1A2, an increase in levels of CYP1A1-mediated
261 formation of 9-hydroxyellipticine and 7-hydroxyellipticine was mediated by
262 cabozantinib (Fig. 3A). In the case of human CYP1A1, this TKI (cabozantinib) also
263 stimulated oxidation of ellipticine to 12-hydroxyellipticine, while lenvatinib increased
264 the formation of 13-hydroxyellipticine (Fig. 3B). Oxidation of ellipticine by rat CYP1A2
265 also resulted in formation of low amounts of 7-hydroxyellipticine, formation of which
266 was increased by vandetanib and cabozantinib during reactions catalyzed by rat
267 CYP1A2. Cabozantinib also stimulated oxidation of ellipticine to 9-hydroxyellipticine
268 in this rat enzymatic system (Fig. 3C). TKIs did not inhibit any of the ellipticine
269 metabolites formed by human CYP1A2. Of note, 12-hydroxyellipticine is formed at
270 very low amounts by this human CYP (CY1A2), and therefore, it was not quantified
271 (Fig. 3D).

272 In contrast to CYP1A1 and 1A2, TKIs inhibited oxidation of ellipticine catalyzed
273 by CYP2D6 > 2D1 > 2C9 > 3A1 > 3A4, the CYP enzymes participating in ellipticine
274 oxidation to metabolites increasing the ellipticine anticancer efficiency (Figs. 3 and 4).
275 Concerning the degree of inhibition effects of TKIs on these ellipticine metabolites,
276 the formation of ellipticine N^2-oxide predominantly catalyzed by human CYP2D6 (Fig.
277 4), which is also the major enzyme forming this ellipticine metabolite, was the most
278 prominent inhibition caused by all analyzed TKIs. This human CYP (CYP2D6) and its
279 rat orthologue (CYP2D1) did not oxidize ellipticine to 7-hydroxyellipticine (Fig. 4). The
280 ellipticine N^2-oxide is the important activation metabolic product, because it forms 12-
281 hydroxyellipticine (by Polonowski rearrangement) [Stiborova et al., 2004], which
282 finally forms ellipticine-12-ylium generating DNA adducts (Fig. 1). Its formation by
283 CYP2D1 was also inhibited by TKIs, but to a lower extent. On the contrary, no
284 inhibition of production of this metabolite catalyzed by CYP3A4 (in the presence of
285 cytochrome b_5) was observed (Fig. 4F).

286 Another activation metabolite, 12-hydroxyellipticine, formed by most analyzed
287 CYPs was not inhibited by tested TKIs. This is unexpected finding when we compare
288 the results showing the inhibition of 12-hydroxyellipticine formation in hepatic
289 microsomes; a decrease in amounts of this metabolite formed in microsomes was
290 produced by TKIs (see Fig. 2). We can speculate that this observed inhibition of 12-
291 hydroxyellipticine formation (catalyzed by many CYPs in hepatic microsomes and
292 also rearranged from ellipticine N^2-oxide) might result from inhibition of its primarily
293 formed ellipticine N^2-oxide that therefore cannot be rearranged to 12-
294 hydroxyellipticine and thus also not inhibited. This suggestion needs, however, to be
295 investigated in further studies.

296 Oxidation of ellipticine to 13-hydroxyellipticine, the most important activation
297 metabolite generating DNA adducts, was inhibited by lenvatinib in the enzymatic
298 system of CYP3A4 and by all TKIs in the system of CYP3A1. But inhibition of 13-
299 hydroxyellipticine formation catalyzed by the CYP3A1 mediated by vandetanib and
300 lenvatinib was not significant (P = 0.06 and P = 0.08, respectively) (Fig. 4). The
301 CYP3A enzymes oxidized ellipticine up to four metabolites, 13-hydroxyellipticine
302 being the predominant oxidation product. Whereas 9-hydroxy-, 12-hydroxy-, 13-
303 hydroxyellipticine are formed by CYP3A1, the human orthologue CYP3A4 can also
304 generate ellipticine N^2-oxide, but only when cytochrome b_5 is present in the reaction
305 mixture. No 7-hydroxyellipticine was formed by CYP3A1/4 (Fig. 4D-F). The found
306 results indicate that inhibition of 13-hydroxyellipticine formation in hepatic
307 microsomes by vandetanib and cabozantinib might be attributed to CYP3A enzymes.
308 However, no inhibition of 13-hydroxyellipticine formation by lenvatinib, found in both
309 used subcellular enzymatic systems (rat and human hepatic microsomes) indicates
310 that the situation in these microsomal systems is more complex. Now, we can only
311 speculate on the reasons of these results. One of them can be the influence of
312 lenvatinib on 13-hydroxyellipticine formation catalyzed by CYP1A1 that stimulates 13-
313 hydroxyellipticine formation; namely, cytochrome b_5 that is the heme protein highly
314 expressed in hepatic microsomal system is known to increase the CYP1A1-mediated
315 formation of 13-hydroxyellipticine in microsomes [Kotrbova et al., 2011; Stiborova et
316 al., 2012b]. This feature might partially compensate the inhibition of its formation
317 caused by other CYP enzymes in microsomes. However again, such suggestion
318 needs to be evaluated in future study.

319 *The effect of vandetanib, lenvatinib and cabozantinib on ellipticine oxidation*
320 *catalyzed by peroxidases*

321 Oxidation of ellipticine to its major metabolite formed by peroxidases HRP, LPO
322 and MPO, ellipticine dimer, which is considered to be a detoxification reaction
323 product of peroxidase-mediated ellipticine oxidation [Stiborova et al., 2007], was
324 utilized to investigate the effect of TKIs on reaction catalyzed by peroxidases. All
325 tested peroxidases oxidized ellipticine to this metabolite, but to a different extent (Fig.
326 5). The tested TKIs had essentially no effect on formation of ellipticine dimer
327 catalyzed by these peroxidases; only cabozantinib slightly increased oxidation of
328 ellipticine by HRP while lenvatinib slightly inhibited the reaction catalyzed by LPO.
329

330 **CONCLUSIONS**

331 The results of this study demonstrate that oxidation of anticancer drug ellipticine
332 mediated by CYP enzymes expressed in rat and human hepatic microsomal
333 subcellular fractions, which determines its pharmacological (anticancer) efficiencies,
334 is influenced by TKIs vandetanib, lenvatinib and cabozantinib. The combination
335 effects of ellipticine with tested TKIs were investigated, because they are the drugs
336 utilized for treatment of thyroid gland cancer, exhibiting specific efficiencies to the
337 individual types of this cancer [Reibenwein et al., 2008; Hartmann et al., 2009;
338 Stiborova and Frei 2014]. But, they act by different mechanisms; the DNA is target for
339 ellipticine action, while TKIs regulate signaling of their enzymatic targets, TKs
340 [Greenhill, 2017; Roviello et al., 2018; Abdelaziz and Vaishampayan, 2017]. What is
341 however not known is whether they can influence the anticancer potency of them.
342 Especially, it is not known whether TKIs can affect the metabolism of ellipticine,
343 which dictate its DNA-damaging efficiency, thereby modulating its therapeutic effects
344 when administered in combinations.

The data found demonstrate that TKIs vandetanib, lenvatinib and cabozantinib inhibit the *in vitro* oxidative activation of ellipticine catalyzed by several CYP enzymes and hepatic subcellular systems expressing these enzymes, which might lead to a decrease in ellipticine anticancer efficiency. In contrast, they practically do not influence its detoxification catalyzed by CYP1A1, 1A2 and peroxidases. All these results suggest that the TKIs might decrease the ellipticine-DNA-damaging effect mediated by the tested enzymes, thereby being ineffective to increase ellipticine anticancer efficiency. The *vice versa* effects, namely the influence of ellipticine on enzyme-mediated metabolism of the tested TKIs, which has not been unfortunately studied in details as yet [Martin et al., 2012; Lacy et al., 2015; Nguyen et al., 2015; Shumaker et al., 2015; Dubbelman et al., 2016], are the challenge of our future research.

ACKNOWLEDGEMENTS

Financial support from GACR (grant 18-10251S) is highly acknowledged. Work at King's College London is supported by the Wellcome Trust (Grants 101126/Z/13/Z and 101126/B/13/Z) and in part by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England (PHE) and Imperial College London. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, the Department of Health & Social Care or PHE.

REFERENCES

369 1. Abdelaziz A and Vaishampayan U (2017) Cabozantinib for renal cell carcinoma:
370 Current and future paradigms. *Curr Treat Options Oncol* 18: 18.
371 2. Arora A and Scholar EM. (2005). Role of tyrosine kinase inhibitors in cancer
372 therapy. *J Pharmacol Exp Ther* 315: 971-979.
373 3. Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM and Stiborova
374 M (2018) The histone deacetylase inhibitor valproic acid exerts a synergistic
375 cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells. *Int J*
376 *Mol Sci* 19: pii: E164.
377 4. Dostalova S, Cerna T, Hynek D, Koudelkova Z, Vaculovic T, Kopel P, Hrabeta J,
378 Heger Z, Vaculovicova M, Eckschlager T, Stiborova M and Adam V (2016) Site-
379 directed conjugation of antibodies to apoferritin nanocarrier for targeted drug
380 delivery to prostate cancer cells. *ACS Applied Materials & Interfaces* 8: 14430-
381 1441.
382 5. Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S,
383 Critchley D, Shumaker R, Schellens JH and Beijnen JH (2016) Metabolite
384 profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species
385 comparison. *Invest New Drugs* 34: 300-318.
386 6. Garbett NC and Graves DE (2004) Extending nature's leads: the anticancer
387 agent ellipticine. *Curr Med Chem Anti-Cancer Agents* 4: 149-172.
388 7. Greenhill C (2017) Therapy: Achieving T2DM remission in primary care. *Nat Rev*
389 *Endocrinol* 14: 66.
390 8. Hartmann JT, Haap M, Kopp HG and Lipp HP (2009) Tyrosine kinase inhibitors -
391 a review on pharmacology, metabolism and side effects. *Curr Drug Metab* 10:
392 470-481.

393 9. Heger Z, Skalickova S, Zitka O, Adam V and Kizek R (2014) Apoferritin
394 applications in nanomedicine. *Nanomedicine (Lond)* 9: 2233-2245.
395 10. Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E and
396 Stiborova M (2012) Anthracyclines and ellipticines as DNA-damaging anticancer
397 drugs: recent advances. *Pharmacol Ther* 133: 26-39.
398 11. Kotrbova V, Aimova D, Brezinova A, Janouchova K, Poljakova J, Hodek P, Frei E
399 and Stiborova M (2006) Cytochromes P450 reconstituted with NADPH:P450
400 reductase mimic the activating and detoxicating metabolism of the anticancer
401 drug ellipticine in microsomes. *Neuro Endocrinol Lett* 27 (Suppl. 2): 18-20.
402 12. Kotrbova V, Mrazova B, Moserova M, Martinek V, Hodek P, Hudecek J, Frei E
403 and Stiborova M (2011) Cytochrome b_5 shifts oxidation of the anticancer drug
404 ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation,
405 thereby modulating its pharmacological efficacy. *Biochem Pharmacol* 82: 669-
406 680.
407 13. Kumarasamy VM and Sun D (2017) Demonstration of a potent RET
408 transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on
409 an ellipticine derivative. *Int J Oncol* 51:145-157.
410 14. Lacy S, Hsu B, Miles D, Aftab D, Wang R and Nguyen L (2015) Metabolism and
411 disposition of cabozantinib in healthy male volunteers and pharmacologic
412 characterization of its major metabolites. *Drug Metab Dispos* 43: 1190-1207.
413 15. Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D and Giles P
414 (2012) Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
415 *Clin Ther* 34: 221-237.
416 16. Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O'Reilly T and Lacy S
417 (2015) Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of

418 CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK
419 and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
420 *J Clin Pharmacol* 55: 1012-1023.
421 17. Poljakova J, Forsterova K, Sulc M, Frei E and Stiborova M (2005) Oxidation of an
422 antitumor drug ellipticine by peroxidases. *Biomed Pap Med Fac Univ Palacky*
423 *Olomouc Czech Repub* 149: 449-453.
424 18. Poljakova J, Hrebackova J, Dvorakova M, Moserova M, Eckschlager T, Hrabeta
425 J, Göttlicherova M, Kopejtkova B, Frei E, Kizek R and Stiborova M (2011)
426 Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic
427 acid and trichostatin A, is an effective DNA damage strategy in human
428 neuroblastoma. *Neuro Endocrinol Lett* 32 (Suppl 1): 101-116.
429 19. Reibenwein J and Krainer M (2008) Targeting signaling pathways in ovarian
430 cancer. *Expert Opin Ther Targets* 12: 353-365.
431 20. Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM
432 Imperatori M, Ianza A, Conca R and Sobhani N (2018*)* Lenvatinib for the
433 treatment of renal cell carcinoma. *Expert Opin Investig Drugs* 27: 507-512.
434 21. Shumaker R, Aluri J, Fan J, Martinez G, Thompson GA and Ren M (2015)
435 Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy
436 participants. *Clin Pharmacol Drug Dev* 4: 155-160.
437 22. Stiborova M, Bieler CA, Wiessler M and Frei E (2001) The anticancer agent
438 ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
439 *Biochem Pharmacol* 62: 1675-1684.
440 23. Stiborova M, Sejbal J, Borek-Dohalska L, Aimova D, Poljakova J, Forsterova K,
441 Rupertova M, Wiesner J, Hudecek J, Wiessler M and Frei E (2004) The
442 anticancer drug ellipticine forms covalent DNA adducts, mediated by human

443 cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine
444 N^2-oxide*. Cancer Res* 64: 8374–8380.

445 24. Stiborova M, Borek-Dohalska L, Aimova D, Kotrbova V, Kukackova K,
446 Janouchova K, Rupertova M, Ryslava H, Hudecek J and Frei E (2006) Oxidation
447 pattern of the anticancer drug ellipticine by hepatic microsomes – Similarity
448 between human and rat systems. *Gen Physiol Biophys* 25: 245-261.

449 25. Stiborova M, Poljakova J, Ryslava H, Dracinsky M, Eckschlager T and Frei E
450 (2007) Mammalian peroxidases activate anticancer drug ellipticine to
451 intermediates forming deoxyguanosine adducts in DNA identical to those found in
452 vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. *Int J*
453 *Cancer* 120: 243-251.

454 26. Stiborova M, Rupertova M and Frei E (2011) Cytochrome P450- and peroxidase-
455 mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor
456 efficiency. *Biochim Biophys Acta* 1814: 175-185.

457 27. Stiborova M, Eckschlager T, Poljakova J, Hrabeta J, Adam V, Kizek R and Frei E
458 (2012a) The synergistic effects of DNA-targeted chemotherapeutics and histone
459 deacetylase inhibitors as therapeutic strategies for cancer treatment. *Curr Med*
460 *Chem* 19: 4218-4238.

461 28. Stiborova M, Poljakova J, Martinkova E, Ulrichova J, Simanek V, Dvorak Z and
462 Frei E (2012b). Ellipticine oxidation and DNA adduct formation in human
463 hepatocytes is catalyzed by human cytochromes P450 and enhanced by
464 cytochrome b_5. *Toxicology*. 302: 233-241.

465 29. Stiborova M and Frei E (2014) Ellipticines as DNA-targeted chemotherapeutics.
466 *Current Med Chem* 21: 575-591.

467 30. Tmejova K, Krejcova L, Hynek D, Adam V, Babula P, Trnkova L, Stiborova M,
468 Eckschlager T and Kizek R (2014) Electrochemical study of ellipticine interaction
469 with single and double stranded oligonucleotides. *Anti-Cancer Agent Med* 14:
470 331-340.
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498

499 **Figure 1.** Scheme of ellipticine metabolism catalyzed by CYPs and peroxidases
500 showing the identified metabolites and those proposed to form DNA adducts. The
501 compounds showed in brackets were not detected under the experimental
502 conditions and/or not yet structurally characterized. The CYP enzymes
503 predominantly oxidizing ellipticine shown in the figure were identified in our previous
504 studies [Stiborova et al., 2004; 2008; 2012b; Kotrbova et al., 2011].
505



506
507
508

509 **Figure 2.** Oxidation of ellipticine by rat (**A**) and human (**B**) hepatic microsomes and
510 the effect of vandetanib, lenvatinib and cabozantinib on this oxidation. The data are
511 averages and standard deviations of three experiments. ***P<0.001; **P<0.01;
512 *P<0.05 (Student's t-test), levels of ellipticine metabolites in the presence of TKIs
513 significantly different from those generated without these inhibitors. NQ – not
514 quantified, ND – not determined. *Insert* in 2A shows HPLC of ellipticine metabolites
515 formed by rat hepatic microsmes. *Insert* in 2B shows HPLC of ellipticine metabolites
516 formed by human microsomes from incubations in the presence of lenvatinib.
517 (**A**)



518

519 **(B)**



520

521 **Figure 3.** Oxidation of ellipticine by rat (**A**) and human (**B**) CYP1A1, rat (**C**) and
522 human CYP1A2 (**D**) and the effect of vandetanib, lenvatinib and cabozantinib on this
523 oxidation. The data are averages and standard deviations of three experiments.
524 ***P<0.001; **P<0.01; *P<0.05 (Student's t-test), levels of ellipticine metabolites in
525 the presence of TKIs significantly different from those generated without these
526 inhibitors. NQ – not quantified, ND – not determined.
527

528 (**A**)



529
530

531 **(B)**



532

533 **(C)**



534

535 **(D)**



536

537

538

539

540

541 **Figure 4.** Oxidation of ellipticine by human CYP2C9 in the presence of cytochrome
542 b_5 (**A**), rat CYP2D1 (**B**), human CYP2D6 (**C**), rat CYP3A1 in the presence of
543 cytochrome b_5 (**D**), human CYP3A4 without (**E**) and in the presence of cytochrome
544 b_5 (**F**) and the effect of vandetanib, lenvatinib and cabozantinib on this oxidation. The
545 data are averages and standard deviations of three experiments. ****P*<0.001;
546 ***P*<0.01; **P*<0.05 (Student's t-test), levels of ellipticine metabolites in the presence
547 of TKIs significantly different from those generated without these inhibitors. NQ – not
548 quantified, ND – not determined.

549 **(A)**



550

551 **(B)**



552

553

554 **(C)**



555

556

557 **(D)**



558

559

560

561

562 **(E)**



563

564

565 **(F)**



566

567

568

569

570 **Figure 5.** Oxidation of ellipticine by HRP (**A**), LPO **B**) and MPO (**C**) to ellipticine
571 dimer and the effect of vandetanib, lenvatinib and cabozantinib on this oxidation.
572 The data are averages and standard deviations of three experiments. ****P*<0.001;
573 ***P*<0.01; **P*<0.05 (Student's t-test), levels of ellipticine metabolites in the presence
574 of TKIs significantly different from those generated without these inhibitors.
575
576 **(A)**



577

578 **(B)**



579

580

581 **(C)**



582

583

584